Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.67 |
| ▸ | HTR3B | O95264 | 2/20 | 0.67 |
| ▸ | HTR3A | P46098 | 2/20 | 0.67 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.67 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | F13A1 | P00488 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | FADS1 | O60427 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28790660 | 0.98 | MEN1 (0.69) | MEN1KMT2AMAPTLMNAHTT | |
| Acetone SCHEMBL11047322 | 0.94 | MEN1 (0.65) | MEN1KMT2AMAPTLMNAHTT | |
| O-Xylene SCHEMBL11044886 | 0.90 | MEN1 (0.59) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL3690365 | 0.85 | MAPT (0.59) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL7173339 | 0.85 | MEN1 (0.67) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL2682054 | 0.83 | KMT2A (1.00) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL11449846 | 0.83 | IDO1 (0.66) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL4108214 | 0.83 | MEN1 (0.59) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL18530322 | 0.82 | MEN1 (0.68) | MEN1KMT2AMAPTLMNAHTT | |
| Bicarbonate SCHEMBL15057748 | 0.82 | MEN1 (0.62) | MEN1KMT2AMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697791-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS Innopharm (Shanghai) Ltd. (CN) | 2020-08-26 | — | — | EP | claimed |
| WO-2019076358-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-04-25 | — | — | WO | claimed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | claimed |
| CN-104194260-A | Composite material connector for pipeline connection | QINGDAO SHENDA HIGH TECH DEV CO LTD | 2014-12-10 | — | — | CN | claimed |
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | claimed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | claimed |
| EP-2285879-A1 | IMPROVED CONDUCTIVITY OF RESIN MATERIALS AND COMPOSITE MATERIALS | Hexcel Composites Limited (GB) | 2011-02-23 | — | — | EP | claimed |
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER CORPSCIENCE AG (DE) | 2010-07-01 | — | — | US | claimed |
| EP-2198710-A1 | Use of 5-pyridin-4yl-(1,3) thiazoles for combating phytopathogenic fungi | Bayer CropScience AG (DE) | 2010-06-23 | — | — | EP | claimed |
| WO-2009147415-A1 | IMPROVED CONDUCTIVITY OF RESIN MATERIALS AND COMPOSITE MATERIALS | HEXCEL COMPOSITES LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| CN-1942475-A | Substituted thieno - and thiazolo - [2, 3-d] pyridines as inhibitors of Tie2 | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | claimed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| CN-1678573-A | Diaryl urea derivatives and their use as chlorine channel blockers | NEUROSEARCH AS (DK) | 2005-10-05 | — | — | CN | claimed |
| CN-1192015-C | Cell adhesion inhibitors | BIOGEN INC (US) | 2005-03-09 | — | — | CN | claimed |
| CN-1270592-A | Spiroazabicyclic heterocyclic compounds | ASTRA AB (SE) | 2000-10-18 | — | — | CN | claimed |
| EP-1005459-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | claimed |
| CN-1075717-A | Benzodiazepine * derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-09-01 | — | — | CN | claimed |
| US-4250319-A | RIPENER FOR SUGARCANE | W. R. GRACE & CO. (US) | 1981-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | PIR, PNPO, PDXK | MEN1 1783/4885KMT2A 2548/4885MAPT 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.